Literature DB >> 27623071

SP110 and PMP22 polymorphisms are associated with tuberculosis risk in a Chinese-Tibetan population.

Guoxia Ren1,2, Jiangtao You3, Xianfeng Gong2, Xiucheng Zhang2, Lin Zhao2, Xianglan Wei2, Tianbo Jin4,5,6, Mingwei Chen1.   

Abstract

Susceptibility to tuberculosis (TB) is partially dependent on host genetic variability. SP110 and PMP22 are candidate genes identified in this study as associated with human susceptibility to TB. Here we performed an association analysis in a case-control study of a Tibetan population (217 cases and 383 controls). Using bioinformatics methods, we identified two SNPs in SP110 that may decrease susceptibility to TB (rs4327230, p<0.001, OR: 0.37, 95%CI: 0.25-0.55; rs2114591, p<0.001, OR: 0.59, 95%CI: 0.45-0.78), whereas one SNP in PMP22 appeared to increase TB risk (rs13422, p=0.003, OR: 1.45, 95%CI: 1.14-1.84). SNPs rs4327230 and rs2114591 remained significant after Bonferroni correction (p<0.00178). We found that the "GC" haplotype in SP110 was protective against TB, with a 64% reduction in disease risk. "CA" and "CG" in PMP22 were also associated with a protective effect. Our study indicates there is an association between specific gene polymorphisms and TB risk in a Tibetan population, and may help to identify those TB-affected individuals most susceptible to disease.

Entities:  

Keywords:  PMP22; SP110; Tibet; single nucleotide polymorphism (SNP); tuberculosis (TB)

Mesh:

Substances:

Year:  2016        PMID: 27623071      PMCID: PMC5323218          DOI: 10.18632/oncotarget.11847

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Tuberculosis (TB) is a highly infectious respiratory disease that remains one of the world's deadliest communicable diseases. According to the World Health Organization (WHO), an estimated 9 million people developed TB and 1.5 million died of the disease in 2013. Although one third of the world's population is infected with the bacillus Mycobacterium tuberculosis, the causative agent of TB, only about 10% will eventually develop clinical disease [1]. Whether or not an individual ultimately develops active disease depends upon both the host immune response and environmental aspects [2]. Genetic factors play an important role in immune system function and are thought to be the key factor in determining an individual's susceptibility to TB [2-5]. The SP110 gene on chromosome 2 encodes a leukocyte-specific nuclear body component that can function as an activator of gene transcription and may serve as a nuclear hormone receptor coactivator. SP110 is a promising candidate gene in the regulation of individual susceptibility to M. tuberculosis. First reported by Pan H, et al. [6], SP110 is the closest human homolog of the mouse gene Ipr1 (Intracellular Pathogen Resistance 1), which protects against tuberculosis by encoding Speckled proteins (SP) that regulate cell activation, division and apoptosis [7]. Previous studies associated SP110 polymorphisms and susceptibility to TB in north Indian [8], Vietnamese [9] and Chinese Han [10] populations, although some groups reported negative results [11, 12]. In addition, the PMP22 (peripheral myelin protein 22) gene on chromosome 17, previously reported to be associated with Charcot Marie Tooth (CMT) disease or hereditary neuropathy with pressure palsies (HNPP), may also play an important role in susceptibility to TB [13-15]. However, neither SP110 nor PMP22 has yet been investigated with respect to TB in the Tibetan population. To investigate the association between SP110 and PMP22 and TB risk in Tibetans, we performed an association analysis in a case-control study. Our findings will help to improve patient-specific TB treatment and diagnosis options in the Tibetan population.

RESULTS

We recruited 217 cases (118 males and 99 females; average age at diagnosis: 49.9) and 383 controls (153 males and 230 females; average age: 20.3) for this study (Table 1). Multivariate analyses were adjusted for age and sex.
Table 1

Patient demographics

VariablesCase (N=217)Control (N=383)Totalp-value
Sex, No.(%)< 0.05a
 Male118 (43.3)153 (60)287 (52.5)
 Female99 (56.7)230 (40)260 (47.5)
Mean age ±SD33.2 ±2.7549.9 ±5.14< 0.05b

P values was calculated from Pearson's chi-square tests.

P values was calculated by Welch's t tests.

P values was calculated from Pearson's chi-square tests. P values was calculated by Welch's t tests. To design the multiplexed SNPs MassEXTEND assay, we used Sequenom MassARRAY Assay Design 3.0 Software (PCR primers are shown in Table 2). A total of seven SNPs (four in SP110 and three in PMP22) were identified in cases and controls. All SNP call rates exceeded 98.2%, which was considered high enough to perform association analyses. SNPs in controls were all in Hardy-Weinberg equilibrium (HWE) (Table 3). We found three SNPs in SP110 (rs6436917, p=0.022, OR: 1.32, 95%CI: 1.04–1.67; rs4327230, p<0.001, OR: 0.37, 95%CI: 0.25–0.55; rs2114591, p<0.001, OR: 0.59, 95%CI: 0.45–0.78) and one in PMP22 (rs13422, p=0.003, OR: 1.45, 95%CI: 1.14–1.84) that exhibited differential allele frequency distributions in cases vs. controls. Rs4327230 and rs2114591 in SP110 remained significant after Bonferroni correction (p<0.00178).
Table 2

PCR primers used in this study

SNP_ID1st-PCR primer2nd-PCR primerUEP_SEQ
rs6436917ACGTTGGATGGCCAATTGTAAGTGCCAAAGACGTTGGATGATGGCCCTAAAATGTTCCACggAATGTTCCACAGTGGGC
rs4327230ACGTTGGATGACAATAGCAAAGACATGGGCACGTTGGATGTATGGCTGCATAGTATTCCGACATATTCTTTATCCAGTCTATAATT
rs2114591ACGTTGGATGGAGACGTACAGAAAAGAGGGACGTTGGATGCTTCCAACAACCACTGTCACaacaACTGTCACATCAACAGATCC
rs7580912ACGTTGGATGACACCCTCTCTCCTAACTACACGTTGGATGGTCTCAAACCACAAACCACCaaaaaCACAAACCACCAGGGCTTCC
rs13422ACGTTGGATGTTGGGATTTTGGGCTAGCTCACGTTGGATGTCTGAGCGTACATAGGGAAGggagcGGGAAGGGAGGAAGGGAAA
rs230915ACGTTGGATGCAAGAAGCCTTTCAGTTGAGACGTTGGATGCCTGACTCTTAGTAAGTCAAttttcAGTAAGTCAATAGAGTGCTGC
rs231024ACGTTGGATGAGCTGGATAAACAGGTCTGGACGTTGGATGCCATGCCTGGCCATCTTATTgGGCCATCTTATTATTATTTAATGA

UEP: Unextended mini-sequencing primer.

Table 3

Allele frequencies in cases and controls and odds ratio estimates for TB

SNP IDGenePositionAlleles Aa/Bp valueMAFHWE pORs(95%CI)p value
casecontrol
rs6436917SP110231038160G/A0.0221*0.5140.4451.00001.32 (1.04,1.67)0.0221*
rs4327230SP110231046783G/C0.0001*0.0780.1880.73790.37 (0.25,0.55)0.0001*
rs2114591SP110231050569C/T0.0002 *0.2030.3020.33170.59 (0.45,0.78)0.0002 *
rs7580912SP110231081405C/T0.71040.3990.3880.51821.05 (0.82,0.14)0.7104
rs13422PMP2215134175A/C0.0025*0.4470.3580.43581.45 (1.14,1.84)0.0025*
rs230915PMP2215148256G/A0.25310.2680.2990.80600.86 (0.66,1.12)0.2531
rs231024PMP2215157972A/G0.07000.2810.3320.41930.79 (0.61,1.02)0.0700

MAF, minor allelic frequency; HWE, Hardy-Weinberg Equilibrium; ORs, odds ratios; CI: confidence interval.

Minor allele; *p≤0.05.

Bonferroni's multiple adjustment was applied, with p<0.00178 (0.05/28).

UEP: Unextended mini-sequencing primer. MAF, minor allelic frequency; HWE, Hardy-Weinberg Equilibrium; ORs, odds ratios; CI: confidence interval. Minor allele; *p≤0.05. Bonferroni's multiple adjustment was applied, with p<0.00178 (0.05/28). We then analyzed associations between SP110 and PMP22 genotypes and TB susceptibility (Table 4). Genotypes “GG” in rs6436917 (p=0.021, OR: 1.72, 95%CI: 1.08–2.74) and “AA” in rs13422 (p=0.002, OR: 2.20, 95%CI: 1.32–3.66) were associated with TB risk. A protective effect was also associated with genotypes “GG” in rs4327230 (p=0.035, OR: 0.23, 95%CI: 0.05–1.02) and “CC” in rs2114591 (p=0.004, OR: 0.35, 95%CI: 0.17–0.73). The “GG” genotype of rs4327230 remained significant after Bonferroni correction.
Table 4

Association between SP110 and PMP22 tSNP genotypes and TB risk

SNP_IDGenotypeNo. (Frequency)OR95%CIp value
CaseControl
rs6436917GG61 (28.24%)76 (19.84%)1.721.08,2.740.021
GA100 (46.30%)189 (49.35%)1.140.76,1.700.536
AA55 (25.46%)118 (30.81%)1-
rs4327230GG2 (0.92%)12 (3.13%)0.230.05,1.020.035
GC30 (13.82%)120 (31.33%)0.340.21,0.53<0.001*
CC185 (85.25%)251 (65.54%)1-
rs2114591CC10 (4.61%)39 (10.18%)0.350.17,0.7300.004*
CT68 (31.34%)153 (39.95%)0.610.43,0.880.007*
TT139 (64.06%)191 (49.87%)1-
rs7580912CC34 (15.67%)54 (14.10%)1.130.68,1.890.639
CT105 (48.39%)189 (49.35%)1.000.69,1.440.988
TT78 (35.94%)140 (36.55%)1-
rs13422AA42 (19.35%)45 (11.81%)2.201.32,3.660.002*
AC110 (50.69%)183 (48.03%)1.410.97,2.060.069
CC65 (29.95%)153 (40.16%)1-
rs230915GG13 (6.10%)35 (9.26%)0.620.32,1.220.165
GA88 (41.31%)156 (41.27%)0.940.66,1.340.738
AA112 (52.58%)187 (49.47%)1-
rs231024AA16 (7.37%)38 (9.92%)0.630.34.1910.154
AG90 (41.47%)178 (46.48%)0.760.54,1.080.124
GG111 (51.15%)167 (43.60%)1-

OR: odd ratio; CI: confidence interval.

*p≤0.05.

Bonferroni's multiple adjustment was applied, with p<0.00178 (0.05/28).

OR: odd ratio; CI: confidence interval. *p≤0.05. Bonferroni's multiple adjustment was applied, with p<0.00178 (0.05/28). We assumed that the minor allele of each SNP was a TB risk factor compared to the wild type allele and analyzed associations between SNPs and TB in various inheritance models (Table 5). Rs6436917 was associated with TB risk in a recessive model (p=0.019, OR: 1.59, 95%CI: 1.06–2.39), while rs4327230 was significant in a dominant model (p<0.001, OR: 0.33, 95%CI: 0.21–0.51). Two other SNPs were associated with TB in both dominant (rs2114591, p<0.001, OR: 0.56, 95%CI: 0.39–0.80; rs13422, p=0.013, OR: 1.57, 95%CI: 1.09–2.28) and recessive models (rs2114591, p=0.017, OR: 0.43, 95%CI: 0.19–0.89; rs13422, p=0.012, OR: 1.79, 95%CI: 1.10–2.91). Rs4327230 and rs2114591 remained significant in the dominant model after Bonferroni correction (p<0.00178).
Table 5

Association between SP110 and PMP22 tSNPs and TB risk based on different inheritance models

SNP_IDModelGenotypeCaseControlOR95%CIp value
rs6436917DominantG-G/G-A1612651.300.88,1.940.1656
A-A55118
RecessiveG-G61761.591.06,2.390.0188*
G-A/A-A155307
rs4327230DominantG-G/G-C321320.330.27,0.510.0001*
C-C185251
RecessiveG-G2120.290.03,1.310.0847
G-C/C-C215371
rs2114591DominantC-C/C-T781920.560.393,0.800.0008*
T-T139191
RecessiveC-C10390.430.19,0.890.0166*
C-T/T-T207344
rs7580912DominantC-C/C-T1392431.030.72,1.480.8816
T-T78140
RecessiveC-C34541.130.69,1.840.6017
C-T/T-T183329
rs13422DominantA-A/A-C1522281.571.08,2.280.0127*
C-C65153
RecessiveA-A42451.791.10,2.910.0119*
A-C/C-C175336
rs230915DominantG-G/G-C1011910.880.62,1.250.4676
C-C112187
RecessiveG-G13350.640.30,1.270.1775
G-C/C-C200343
rs231024DominantA-A/A-G1062160.740.52,1.050.0748
G-G111167
RecessiveA-A16380.730.37,1.370.2946
A-G/G-G201345

OR: odd ratio; CI: confidence interval.

*p≤0.05.

Bonferroni's multiple adjustment was applied, with p 0.00178 (0.05/28).

OR: odd ratio; CI: confidence interval. *p≤0.05. Bonferroni's multiple adjustment was applied, with p 0.00178 (0.05/28). We detected two blocks in SP110 and PMP22 via haplotype analysis (Figure 1 & 2). Block 1 in SP110 included rs4327230 and rs2114591 and Block 2 in PMP22 included rs13422 and rs230915. The global result for Block 1 (rs4327230 and rs2114591) was: total case = 434, total control = 766, global χ2 = 26.416 while df = 2, Pearson's p value<0.001. The result for Block 2 (rs13422 and rs230915) was: total case = 434, total control = 766, global χ2=10.567 while df = 3, Pearson's p value=0.014. We did not perform Fisher's exact probabilities because the total sample size exceeded 40 and all theoretical frequencies were >1.
Figure 1

Haplotype block map for SP110 tSNPs

Block 1 includes rs4327230 and rs2114591. The coefficient of linkage disequilibrium (D) between two SNPs is normalized to D' (D/Dmax) (red schemes).

Figure 2

Haplotype block map for PMP22 tSNPs

Block 2 includes rs13422 and rs230915. The coefficient of linkage disequilibrium (D) between two SNPs is normalized to D' (D/Dmax) (red schemes).

Haplotype block map for SP110 tSNPs

Block 1 includes rs4327230 and rs2114591. The coefficient of linkage disequilibrium (D) between two SNPs is normalized to D' (D/Dmax) (red schemes).

Haplotype block map for PMP22 tSNPs

Block 2 includes rs13422 and rs230915. The coefficient of linkage disequilibrium (D) between two SNPs is normalized to D' (D/Dmax) (red schemes). Further analyses of associations between SP110 and PMP22 haplotypes and TB risk showed that haplotype “GC” in Block 1 was protective against TB (p<0.001, OR: 0.36, 95%CI: 0.24–0.54), which remained significant after Bonferroni correction (p<0.00178) (Table 6). Both haplotypes “CA” (p=0.024, OR: 0.71, 95%CI: 0.53–0.96) and “CG” (p=0.021, OR: 0.70, 95%CI: 0.52–0.95) were also protective against TB. These results suggested that rs13422 allele A might be a risk factor for TB susceptibility.
Table 6

Association of haplotype frequencies with TB risk in cases and controls

BlockSNPsHaplotypesFrequenciesχ2Pearson's pOR95%CI
casecontrol
1rs4327230 | rs2114591CT0.7970.698--1 (reference)-
GC0.0780.18826.365<0.001*0.360.24-0.54
CC0.1240.1140.3140.840.960.68-1.37
2rs13422 | rs230915AA0.4290.351--1 (reference)-
CA0.3020.3502.8690.024*0.710.53-0.96
CG0.2510.2912.2030.021*0.700.52-0.95
AG0.0180.0082.5180.1902.600.62-10.90

OR: odd ratio; CI: confidence interval

Bonferroni's multiple adjustment was applied, with p<0.00178 (0.05/28).

OR: odd ratio; CI: confidence interval Bonferroni's multiple adjustment was applied, with p<0.00178 (0.05/28).

DISCUSSION

Multiple groups have investigated associations between SP110 and TB susceptibility in a variety of populations, but these study results are generally considered controversial [8-10, 12, 16-18]. In the current case-control study, we investigated seven total SNPs in a Tibetan population and found that three in SP110 (rs6436917, rs4327230, rs2114591) and one in PMP22 (rs13422) were associated with TB risk. To the best of our knowledge, this is the first study to demonstrate an association between PMP22 and TB, and the first study of SP110 in Tibetans. We found that the “GC” haplotype in SP110 was protective against TB, with a 64% reduction in disease risk. “CA” and “CG” in PMP22 were also associated with a protective effect. Two SP110 SNPs, rs2114591 and rs6436917, were particularly notable in this study. The rs2114591 C allele in intron 11 of SP110 greatly reduced TB risk in the study population. However, a previous study by Abhimanyu, et al. [8] showed no association between rs2114591 and TB in lymph node tuberculosis in north Indians. Moreover, neither Thye, et al. [12] nor Png, et al. [17] found any association between rs2114591 and TB risk in Indonesians or the republic of Ghana, respectively. Rs6436917 was also associated with TB in our study. Abhimanyu, et al. [8] did not detect this SNP in their study, but instead associated another SNP 3636 bp upstream of rs6436917, rs6436915, with TB risk (OR=3, 95%CI, 1.3-6.3; p=0.0057). Our study and others indicate that gene expression may differ among races, and this should be taken into consideration when determining an individual patient's susceptibility to TB. PMP22 encodes an integral membrane protein that is a major component of myelin in the peripheral nervous system. It is expressed in Schwann cells and also in non-neural cells such as the lung epithelium, and influences cell proliferation [19]. In the current study, we identified the rs13422 A allele in the PMP22 3′UTR as a TB risk factor in a Tibetan population. This is the first study to associate PMP22 and TB risk. TB elicits a kind of type IV allergic reaction (also called delayed type hypersensitivity, DTH). The main pathological processes involved include exudation, alteration and proliferation, which depend on both the host immune system and M. tuberculosis strain virulence. Mouse models have been employed to explore the impacts of Ipr1, encoded within the sst1 locus, on TB susceptibility. Kramnik [7] showed that sst1 gene expression may be regulated by macrophages in a cell-autonomous manner. Chackerian, et al. [20] also found increased numbers of IFN-γ-producing CD4+ T cells in the lungs of sst1-resisitant C57BL/6 inbred mice, and conjectured that TB susceptibility was related to the ability to recruit mycobacteria-specific IFN-γ-producing Th1 cells to the lungs. Mechanisms of TB resistance via Ipr1 and sst1 have been extensively explored, but studies of SP110 with respect to TB in humans are rare, and no work had yet addressed PMP22, which is primarily associated with neural diseases, in TB. Though we found that PMP22 is a risk factor for TB, the mechanisms by which PMP22 affects immunity are unknown and require further study. The Bonferroni correction is one of the most important methods used to address false discovery rates resulting from multiple testing. We found that SNPs rs4327230 and rs2114591 remained significant after Bonferroni correction, while rs6436917 and rs13422 were not associated with TB. This may due to our strict SNP filtering criteria and small sample size. Additionally, the Bonferroni correction adjusts the value of alpha based on the number of tests performed, and is thus conservative; in some cases, truly significant differences may be deemed non-significant as a result of type II errors [21]. Our study faced some intrinsic limitations. Our patient sample size (217 cases and 383 controls) was not large enough for the association analysis. Other studies included more than 1000 samples [22], and their SNP-TB association findings are therefore more reliable. Additionally, the case groups we selected included patients diagnosed with clinical tuberculosis (sputum smear-positive), regardless of their typing, which could potentially reduce the validity of our conclusions. Our study provides new evidence supporting the importance of host genetic variability in TB susceptibility. We identified SP110 genotypes that appear protective against TB, and identified PMP22 genotypes as risk factors in TB susceptibility. Our study may help to identify those TB-affected individuals most susceptible to disease, and to improve patient-specific clinical TB diagnosis.

MATERIALS AND METHODS

Ethics statement

We strictly obeyed the World Medical Association Declaration of Helsinki when using human tissue and signing the study protocol with subjects, which was approved by the Ethical Committee of Xi'an Jiaotong University. Each participant provided written, informed consent.

Subjects

All participants in our study were Tibetan Chinese. A total of 143 TB patients were consecutively recruited between March 2013 and June 2015 in the Tangdu Hospital, affiliated with The Fourth Military Medical University in Xi'an city, China. Patients were diagnosed with TB using symptoms and signs, chest X-ray, sputum smear test for acid fast bacilli (AFB) and M. tuberculosis sputum culture. All patients were HIV negative, which was confirmed by the HIV serology test. There were no age, sex or TB classification restrictions when enrolling the case group. Controls were healthy people receiving physical examinations in other clinical departments of Tangdu Hospital. Healthy controls did not have respiratory disease, immune system disease or any other infectious disease, such as acquired immunodeficiency syndrome (AIDS), that could have affected our study results. Peripheral blood was collected from both cases and controls for DNA extraction.

Clinical data and patient demographics

A standardized epidemiological questionnaire was provided to all subjects to collect basic demographic information, including sex, age, residence, educational status, history of family cancer, history of smoking, alcohol consumption and TB contact history. Plasma carcinoembryonic antigen and alpha-fetoprotein levels were determined to ensure that no controls suffered any cancer.

SNP selection and genotyping

Candidate SNPs in the SP110 and PMP22 genes were selected from previous publications that associated polymorphisms with TB [23, 24]. SNPs with minor allele frequencies (MAF) > 5% in the HapMap CHB population were selected. We validated four SNPs in SP110 and three in PMP22. The GoldMag-Mini Purification Kit (GoldMag Co. Ltd. Xian city, China) was used to extract genomic DNA from whole blood samples. DNA concentration was measured using a DU530 UV/VIS spectrophotometer (Beckman Instruments, Fullerton, CA, USA). Using MassARRAY Assay Design 3.0 software (Sequenom, San Diego, CA, USA), we designed a multiplexed SNP MassEXTENDED assay. SNPs were genotyped using the standard protocol recommended by the MassARRAY RS1000 (Sequenom) manufacturer and data were analyzed using Typer 4.0 Software (Sequenom).

Statistical analysis

We used Microsoft Excel and SPSS 16.0 (SPSS, Chicago, IL) statistical packages to perform statistical analyses. All p-values were two-sided and p<0.05 was considered statistically significant. A t test and Chi-square test were performed to compare sex and age differences between cases and controls. Fisher's exact test was applied to each SNP in the controls to test for departure from Hardy–Weinberg Equilibrium (HWE). Odds ratios (ORs) and 95% confidence intervals (CIs) for the allele and genotype frequencies were calculated using Pearson Chi-square test adjusted by age and gender. Cochran-Armitage trend test was performed to determine associations between SNPs and TB. Sex and age subgroups were not separated due to sample size limitations. PLINK software (http://pngu.mgh.harvard.edu/purcell/plink/) was used to assess SNP associations with TB risk in different genetic models (dominant and recessive). We used unconditional logistic regression analysis to calculate ORs and 95% CI adjusted for age and gender. Pairwise linkage disequilibrium and haplotype constructions were performed using HAPLOVIEW 4.1 (http://broad.mit.edu/mpg/haploview) [25]. All p values were Bonferroni corrected, and statistical significance was set at p<0.00178 (0.05/28).
  24 in total

1.  Ipr1 gene mediates innate immunity to tuberculosis.

Authors:  Hui Pan; Bo-Shiun Yan; Mauricio Rojas; Yuriy V Shebzukhov; Hongwei Zhou; Lester Kobzik; Darren E Higgins; Mark J Daly; Barry R Bloom; Igor Kramnik
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

Review 2.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

3.  Resequencing and association analysis of the SP110 gene in adult pulmonary tuberculosis.

Authors:  Jeffrey S Szeszko; Barry Healy; Helen Stevens; Yanina Balabanova; Francis Drobniewski; John A Todd; Sergey Nejentsev
Journal:  Hum Genet       Date:  2006-12-06       Impact factor: 4.132

4.  Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis.

Authors:  A A Chackerian; T V Perera; S M Behar
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Polymorphisms in SP110 are not associated with pulmonary tuberculosis in Indonesians.

Authors:  Eileen Png; Bachti Alisjahbana; Edhyana Sahiratmadja; Sangkot Marzuki; Ron Nelwan; Iskandar Adnan; Esther van de Vosse; Martin Hibberd; Reinout van Crevel; Tom H M Ottenhoff; Mark Seielstad
Journal:  Infect Genet Evol       Date:  2012-04-12       Impact factor: 3.342

6.  The effects of SP110's associated genes on fresh cavitary pulmonary tuberculosis in Han Chinese population.

Authors:  Shi-Yao Jiang; Lin-Lin Li; Jun Yue; Wen-Zhong Chen; Chao Yang; Chun-Ling Wan; Lin He; Lei Cai; Shao-Li Deng
Journal:  Clin Exp Med       Date:  2015-01-23       Impact factor: 3.984

7.  In vivo expression of innate immunity markers in patients with Mycobacterium tuberculosis infection.

Authors:  Pantelis Constantoulakis; Eftihia Filiou; Nikoletta Rovina; George Chras; Aggeliki Hamhougia; Simona Karabela; Adamandia Sotiriou; Charis Roussos; Nikolaos Poulakis
Journal:  BMC Infect Dis       Date:  2010-08-18       Impact factor: 3.090

Review 8.  Molecular mechanisms of alcohol-mediated carcinogenesis.

Authors:  Helmut K Seitz; Felix Stickel
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

9.  An autosomal dominant major gene confers predisposition to pulmonary tuberculosis in adults.

Authors:  Jamila El Baghdadi; Marianna Orlova; Andrea Alter; Brigitte Ranque; Mohamed Chentoufi; Faouzia Lazrak; Moulay Idriss Archane; Jean-Laurent Casanova; Abdellah Benslimane; Erwin Schurr; Laurent Abel
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

Review 10.  Inborn errors of immunity to infection: the rule rather than the exception.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

View more
  4 in total

1.  Local adaptation of Mycobacterium tuberculosis on the Tibetan Plateau.

Authors:  Qingyun Liu; Haican Liu; Li Shi; Mingyu Gan; Xiuqin Zhao; Liang-Dong Lyu; Howard E Takiff; Kanglin Wan; Qian Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-27       Impact factor: 11.205

2.  Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra.

Authors:  Daisy X Ji; Livia H Yamashiro; Katherine J Chen; Naofumi Mukaida; Igor Kramnik; K Heran Darwin; Russell E Vance
Journal:  Nat Microbiol       Date:  2019-10-14       Impact factor: 17.745

3.  Sp110 enhances macrophage resistance to Mycobacterium tuberculosis via inducing endoplasmic reticulum stress and inhibiting anti-apoptotic factors.

Authors:  Yongyan Wu; Zekun Guo; Fayang Liu; Kezhen Yao; Mingqing Gao; Yan Luo; Yong Zhang
Journal:  Oncotarget       Date:  2017-07-17

4.  Association Between Functional Nucleotide Polymorphisms Up-regulating Transforming Growth Factor β1 Expression and Increased Tuberculosis Susceptibility.

Authors:  Su Zhang; Guobao Li; Jing Bi; Qinglong Guo; Xiangdong Fu; Wenfei Wang; Shuyan Liu; Guohui Xiao; Min Ou; Juanjuan Zhang; Xing He; Fang Li; Guanqiang Li; Carl G Feng; Xinchun Chen; Guoliang Zhang
Journal:  J Infect Dis       Date:  2022-03-02       Impact factor: 5.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.